{"name":"Jiangsu Hengrui Medicine","slug":"jiangsu-hengrui","ticker":"600276.SS","exchange":"SSE","domain":"hengrui.com","description":"Jiangsu Hengrui Pharmaceuticals Company Ltd., also known as Jiangsu Hengrui, is a Chinese pharmaceutical company that manufactures and distributes various types of drug packaging materials, cancer-treating antineoplastics, cardiovascular medication, painkillers, antibiotics, and related products. It is the largest listed pharmaceutical company in China.","hq":"Lianyungang, Jiangsu, China","founded":1999,"employees":"20602","ceo":"Sun Piaoyang (Founder & Chair) / Zhou Yunjian (President)","sector":"Oncology / Cardiovascular / Autoimmune","stockPrice":54.32,"stockChange":-1.54,"stockChangePercent":-2.76,"marketCap":"$53.1B","metrics":{"revenue":4799394402.284892,"revenueGrowth":13,"grossMargin":86.3,"rdSpend":0,"netIncome":1196631989.9038105,"cash":5988975761.5011015,"dividendYield":0.36,"peRatio":44.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-12-22","label":"Carelizumab Phase 3 readout (NSCLC (Non-small Cell Lung Cancer))","drug":"Carelizumab","drugSlug":"carelizumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-06-01","label":"Apatinib patent cliff ($1.2B at risk)","drug":"Apatinib","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":41,"colorKey":"immunology","drugs":[{"name":"HR17031 injection","genericName":"HR17031 injection","slug":"hr17031-injection","indication":"Solid tumors (specific indications under investigation in phase 3)","status":"phase_3"},{"name":"HRS-8427","genericName":"HRS-8427","slug":"hrs-8427","indication":"Cancer (specific indication under Phase 3 evaluation)","status":"phase_3"},{"name":"Apatinib Mesylate, Gefitinib","genericName":"Apatinib Mesylate, Gefitinib","slug":"apatinib-mesylate-gefitinib","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"Fuzuloparib , Abiraterone acetate and Prednisone","genericName":"Fuzuloparib , Abiraterone acetate and Prednisone","slug":"fuzuloparib-abiraterone-acetate-and-prednisone","indication":"Metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair deficiency","status":"phase_3"},{"name":"GEMOX","genericName":"GEMOX","slug":"gemox","indication":"Colorectal cancer","status":"phase_2"},{"name":"Irinotecan liposome、5-Fluorouracil、Leucovorin","genericName":"Irinotecan liposome、5-Fluorouracil、Leucovorin","slug":"irinotecan-liposome-5-fluorouracil-leucovorin","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan","genericName":"Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan","slug":"ramucirumab-paclitaxel-docetaxel-irinotecan","indication":"Advanced gastric cancer or gastroesophageal junction cancer (in combination with chemotherapy)","status":"phase_3"},{"name":"SHR-1209","genericName":"SHR-1209","slug":"shr-1209","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"SHR-1314","genericName":"SHR-1314","slug":"shr-1314","indication":"Relapsed or refractory multiple myeloma","status":"phase_3"},{"name":"SHR-1316; Carboplatin; Etoposide；Radiotherapy","genericName":"SHR-1316; Carboplatin; Etoposide；Radiotherapy","slug":"shr-1316-carboplatin-etoposide-radiotherapy","indication":"Small cell lung cancer","status":"phase_3"},{"name":"SHR2554 analog tablets; Chidamide","genericName":"SHR2554 analog tablets; Chidamide","slug":"shr2554-analog-tablets-chidamide","indication":"Relapsed or refractory peripheral T-cell lymphoma","status":"phase_3"},{"name":"Apatinib and Etoposide capsule","genericName":"Apatinib and Etoposide capsule","slug":"apatinib-and-etoposide-capsule","indication":"Metastatic gastric cancer","status":"phase_2"},{"name":"Avastin®, paclitaxel, carboplatin","genericName":"Avastin®, paclitaxel, carboplatin","slug":"avastin-paclitaxel-carboplatin","indication":"Advanced or metastatic non-small cell lung cancer","status":"phase_3"},{"name":"BP102, paclitaxel, carboplatin","genericName":"BP102, paclitaxel, carboplatin","slug":"bp102-paclitaxel-carboplatin","indication":"Non-small cell lung cancer (phase 3)","status":"phase_3"},{"name":"Camrelizumab Plus Chemotherapy","genericName":"Camrelizumab Plus Chemotherapy","slug":"camrelizumab-plus-chemotherapy","indication":"Non-small cell lung cancer (NSCLC) in combination with chemotherapy","status":"phase_3"},{"name":"Carboplatin for Injection","genericName":"Carboplatin for Injection","slug":"carboplatin-for-injection","indication":"Ovarian cancer","status":"phase_3"},{"name":"Enzalutamide Soft Capsules","genericName":"Enzalutamide Soft Capsules","slug":"enzalutamide-soft-capsules","indication":"Metastatic castration-resistant prostate cancer (mCRPC)","status":"phase_3"},{"name":"Fluzoparib Combined With Apatinib","genericName":"Fluzoparib Combined With Apatinib","slug":"fluzoparib-combined-with-apatinib","indication":"Advanced solid tumors","status":"phase_2"},{"name":"Fluzoparib; Apatinib","genericName":"Fluzoparib; Apatinib","slug":"fluzoparib-apatinib","indication":"Ovarian cancer (BRCA-mutated or homologous recombination-deficient)","status":"phase_3"},{"name":"HRS-4357 injection","genericName":"HRS-4357 injection","slug":"hrs-4357-injection","indication":"Advanced or metastatic solid tumors (specific indications under investigation in Phase 3)","status":"phase_3"},{"name":"HRS-4642 + AG","genericName":"HRS-4642 + AG","slug":"hrs-4642-ag","indication":"Advanced or metastatic solid tumors (specific indication under phase 3 evaluation)","status":"phase_3"},{"name":"HRS-9231","genericName":"HRS-9231","slug":"hrs-9231","indication":"Solid tumors (specific indications in phase 3 development)","status":"phase_3"},{"name":"INS068 injection","genericName":"INS068 injection","slug":"ins068-injection","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"Letrozole or Anastrozole Tablets","genericName":"Letrozole or Anastrozole Tablets","slug":"letrozole-or-anastrozole-tablets","indication":"Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic)","status":"phase_3"},{"name":"Palcebo; Carboplatin; Etoposide；Radiotherapy","genericName":"Palcebo; Carboplatin; Etoposide；Radiotherapy","slug":"palcebo-carboplatin-etoposide-radiotherapy","indication":"Likely small cell lung cancer or other solid tumors (specific indication not provided)","status":"phase_3"},{"name":"Placebo, Trastuzumab, Docetaxel","genericName":"Placebo, Trastuzumab, Docetaxel","slug":"placebo-trastuzumab-docetaxel","indication":"HER2-positive breast cancer (metastatic or early-stage)","status":"phase_3"},{"name":"Placebo、5-Fluorouracil、Leucovorin","genericName":"Placebo、5-Fluorouracil、Leucovorin","slug":"placebo-5-fluorouracil-leucovorin","indication":"Colorectal cancer (adjuvant or metastatic)","status":"phase_3"},{"name":"Pyrotinib in combination with Capecitabine.","genericName":"Pyrotinib in combination with Capecitabine.","slug":"pyrotinib-in-combination-with-capecitabine","indication":"Metastatic HER2-positive breast cancer","status":"phase_3"},{"name":"Pyrotinib, Trastuzumab, Docetaxel","genericName":"Pyrotinib, Trastuzumab, Docetaxel","slug":"pyrotinib-trastuzumab-docetaxel","indication":"Advanced or metastatic breast cancer with HER2 overexpression","status":"phase_3"},{"name":"Rezvilutamide Tablets","genericName":"Rezvilutamide Tablets","slug":"rezvilutamide-tablets","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"},{"name":"Rivoceranib (Apatinib)","genericName":"Rivoceranib (Apatinib)","slug":"rivoceranib-apatinib","indication":"Metastatic gastric cancer, Metastatic non-small cell lung cancer","status":"phase_3"},{"name":"SHR-1316、Chemotherapeutic","genericName":"SHR-1316、Chemotherapeutic","slug":"shr-1316-chemotherapeutic","indication":"Solid tumors (specific indications under phase 3 evaluation)","status":"phase_3"},{"name":"SHR-A1811","genericName":"SHR-A1811","slug":"shr-a1811","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"SHR-A1811 Injection ； Pertuzumab Injection","genericName":"SHR-A1811 Injection ； Pertuzumab Injection","slug":"shr-a1811-injection-pertuzumab-injection","indication":"HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","status":"phase_3"},{"name":"SHR0302","genericName":"SHR0302","slug":"shr0302","indication":"Advanced solid tumors","status":"phase_3"},{"name":"SHR2554; Chidamide analog tablets","genericName":"SHR2554; Chidamide analog tablets","slug":"shr2554-chidamide-analog-tablets","indication":"Relapsed or refractory peripheral T-cell lymphoma","status":"phase_3"},{"name":"TACE+Camrelizumab+Apatinib mesylate","genericName":"TACE+Camrelizumab+Apatinib mesylate","slug":"tace-camrelizumab-apatinib-mesylate","indication":"Hepatocellular carcinoma (HCC), unresectable or advanced stage","status":"phase_3"},{"name":"camrelizumab； famitinib malate","genericName":"camrelizumab； famitinib malate","slug":"camrelizumab-famitinib-malate","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"long-acting Octreotide.","genericName":"long-acting Octreotide.","slug":"long-acting-octreotide","indication":"Acromegaly","status":"phase_3"},{"name":"nab-paclitaxel; gemcitabine","genericName":"nab-paclitaxel; gemcitabine","slug":"nab-paclitaxel-gemcitabine","indication":"Pancreatic cancer","status":"phase_3"},{"name":"placebo+chemotherapy","genericName":"placebo+chemotherapy","slug":"placebo-chemotherapy","indication":"Metastatic breast cancer, Metastatic non-small cell lung cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":38,"colorKey":"oncology","drugs":[{"name":"Digoxin tablet","genericName":"Digoxin tablet","slug":"digoxin-tablet","indication":"Other","status":"marketed"},{"name":"ApatinibTablets","genericName":"ApatinibTablets","slug":"apatinibtablets","indication":"Other","status":"marketed"},{"name":"Drug: Pegylated rhG-CSF: 100µg/kg","genericName":"Drug: Pegylated rhG-CSF: 100µg/kg","slug":"drug-pegylated-rhg-csf-100-g-kg","indication":"Chemotherapy-induced neutropenia (CIN)","status":"phase_3"},{"name":"FOLFOX4","genericName":"FOLFOX4","slug":"folfox4","indication":"Other","status":"marketed"},{"name":"HR021618","genericName":"HR021618","slug":"hr021618","indication":"Other","status":"phase_2"},{"name":"HRS-1738 Injection","genericName":"HRS-1738 Injection","slug":"hrs-1738-injection","indication":"Other","status":"phase_1"},{"name":"HRS-6209 in Combination with Letrozole","genericName":"HRS-6209 in Combination with Letrozole","slug":"hrs-6209-in-combination-with-letrozole","indication":"Other","status":"phase_1"},{"name":"Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule","genericName":"Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule","slug":"hetrombopag-olamine-tablet-ciclosporin-soft-capsule","indication":"Other","status":"phase_1"},{"name":"SHR3824","genericName":"SHR3824","slug":"shr3824","indication":"Unknown","status":"phase_3"},{"name":"SHR7280；Ganirelix Acetate Injection simulant","genericName":"SHR7280；Ganirelix Acetate Injection simulant","slug":"shr7280-ganirelix-acetate-injection-simulant","indication":"Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology","status":"phase_3"},{"name":"Carelizumab","genericName":"Carelizumab","slug":"carelizumab","indication":"Other","status":"discontinued"},{"name":"Cipatinib","genericName":"Cipatinib","slug":"cipatinib","indication":"Other","status":"discontinued"},{"name":"FH-006 ; SHR-1316 ; BP102","genericName":"FH-006 ; SHR-1316 ; BP102","slug":"fh-006-shr-1316-bp102","indication":"unknown","status":"phase_2"},{"name":"Fluconazole、Famitinib","genericName":"Fluconazole、Famitinib","slug":"fluconazole-famitinib","indication":"Other","status":"phase_1"},{"name":"HR020602 injection","genericName":"HR020602 injection","slug":"hr020602-injection","indication":"Other","status":"phase_2"},{"name":"HR070803","genericName":"HR070803","slug":"hr070803","indication":"Other","status":"phase_2"},{"name":"HR17031 injection ；INS068 injection；SHR20004 injection","genericName":"HR17031 injection ；INS068 injection；SHR20004 injection","slug":"hr17031-injection-ins068-injection-shr20004-injection","indication":"Other","status":"phase_1"},{"name":"HR19042 Capsules","genericName":"HR19042 Capsules","slug":"hr19042-capsules","indication":"Other","status":"phase_2"},{"name":"HR19042 capsule","genericName":"HR19042 capsule","slug":"hr19042-capsule","indication":"Other","status":"phase_1"},{"name":"HRS-1167","genericName":"HRS-1167","slug":"hrs-1167","indication":"Other","status":"phase_2"},{"name":"HRS-4508 tablet","genericName":"HRS-4508 tablet","slug":"hrs-4508-tablet","indication":"Unknown","status":"phase_2"},{"name":"HRS-5041 tablets","genericName":"HRS-5041 tablets","slug":"hrs-5041-tablets","indication":"Other","status":"phase_1"},{"name":"HRS-9190; under Inhalational Anesthesia","genericName":"HRS-9190; under Inhalational Anesthesia","slug":"hrs-9190-under-inhalational-anesthesia","indication":"Other","status":"phase_2"},{"name":"HRS4800 tablets","genericName":"HRS4800 tablets","slug":"hrs4800-tablets","indication":"Other","status":"phase_2"},{"name":"HS-10296 po","genericName":"HS-10296 po","slug":"hs-10296-po","indication":"Other","status":"phase_2"},{"name":"IvabRadine hemisulfate Sustained-release Tablets","genericName":"IvabRadine hemisulfate Sustained-release Tablets","slug":"ivabradine-hemisulfate-sustained-release-tablets","indication":"Other","status":"phase_2"},{"name":"Morhpine PCA","genericName":"Morhpine PCA","slug":"morhpine-pca","indication":"Other","status":"phase_2"},{"name":"Nifedipine GTIS","genericName":"Nifedipine GTIS","slug":"nifedipine-gtis","indication":"Other","status":"phase_1"},{"name":"Pegylated rhG-CSF: 100µg/kg","genericName":"Pegylated rhG-CSF: 100µg/kg","slug":"pegylated-rhg-csf-100-g-kg","indication":"Chemotherapy-induced neutropenia (CIN)","status":"phase_3"},{"name":"Placebo+Standard Therapy","genericName":"Placebo+Standard Therapy","slug":"placebo-standard-therapy","indication":"Various conditions","status":"phase_3"},{"name":"Placebo、Chemotherapeutic","genericName":"Placebo、Chemotherapeutic","slug":"placebo-chemotherapeutic","indication":"Control arm in chemotherapy clinical trial (specific indication unknown)","status":"phase_3"},{"name":"RSS0343 Tabella","genericName":"RSS0343 Tabella","slug":"rss0343-tabella","indication":"Other","status":"phase_2"},{"name":"Remimazolam Tosilate for Injection","genericName":"Remimazolam Tosilate for Injection","slug":"remimazolam-tosilate-for-injection","indication":"Procedural sedation and anesthesia induction","status":"marketed"},{"name":"SHR-A1811 & Fulvestrant","genericName":"SHR-A1811 & Fulvestrant","slug":"shr-a1811-fulvestrant","indication":"Other","status":"phase_1"},{"name":"SHR2554 Tablets","genericName":"SHR2554 Tablets","slug":"shr2554-tablets","indication":"Other","status":"phase_2"},{"name":"SHR4640","genericName":"SHR4640","slug":"shr4640","indication":"Other","status":"phase_3"},{"name":"SHR7280 simulant； Ganirelix Acetate Injection","genericName":"SHR7280 simulant； Ganirelix Acetate Injection","slug":"shr7280-simulant-ganirelix-acetate-injection","indication":"Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART)","status":"phase_3"},{"name":"SP2086","genericName":"SP2086","slug":"sp2086","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"Noiiglutide Injection","genericName":"Noiiglutide Injection","slug":"noiiglutide-injection","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"SHR8554 Injection","genericName":"SHR8554 Injection","slug":"shr8554-injection","indication":"Treatment of type 2 diabetes","status":"phase_3"},{"name":"Insulin Degludec Injection","genericName":"Insulin Degludec Injection","slug":"insulin-degludec-injection","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Retagliptin, Henagliflozein, metformin XR","genericName":"Retagliptin, Henagliflozein, metformin XR","slug":"retagliptin-henagliflozein-metformin-xr","indication":"Treatment of type 2 diabetes","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"neuroscience","drugs":[{"name":"Sustained-release Metoprolol Succinate","genericName":"Sustained-release Metoprolol Succinate","slug":"sustained-release-metoprolol-succinate","indication":"Hypertension","status":"phase_3"},{"name":"SHR8008 capsule","genericName":"SHR8008 capsule","slug":"shr8008-capsule","indication":"Hypertension","status":"phase_3"},{"name":"SHR6390 Tablets","genericName":"SHR6390 Tablets","slug":"shr6390-tablets","indication":"Atrial fibrillation for stroke prevention","status":"phase_3"},{"name":"SHR8028 eye drops","genericName":"SHR8028 eye drops","slug":"shr8028-eye-drops","indication":"Open-angle glaucoma","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"infectious","drugs":[{"name":"Herombopag tablets","genericName":"Herombopag tablets","slug":"herombopag-tablets","indication":"Thrombocytopenia in patients with chronic liver disease","status":"phase_3"},{"name":"Fluconazole capsule","genericName":"Fluconazole capsule","slug":"fluconazole-capsule","indication":"Candidiasis (oropharyngeal, esophageal, vaginal, and systemic)","status":"phase_3"},{"name":"Hetrombopag Olamine+Standard Therapy","genericName":"Hetrombopag Olamine+Standard Therapy","slug":"hetrombopag-olamine-standard-therapy","indication":"Immune thrombocytopenia (ITP)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"rare","drugs":[{"name":"SHR8058 eye drops","genericName":"SHR8058 eye drops","slug":"shr8058-eye-drops","indication":"Dry eye disease (DED) with neuropathic pain component","status":"phase_3"},{"name":"Pregabalin Release Tablets","genericName":"Pregabalin Release Tablets","slug":"pregabalin-release-tablets","indication":"Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury pain)","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"metabolic","drugs":[{"name":"Vehicle eye drops.","genericName":"Vehicle eye drops.","slug":"vehicle-eye-drops","indication":"Dry eye syndrome","status":"phase_3"},{"name":"saline eye drops.","genericName":"saline eye drops.","slug":"saline-eye-drops","indication":"Dry eye syndrome","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Imipenem and Cilastatin Sodium","genericName":"Imipenem and Cilastatin Sodium","slug":"imipenem-and-cilastatin-sodium","indication":"Serious bacterial infections including lower respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecological infections, and septicemia","status":"marketed"}]}],"pipeline":[{"name":"Digoxin tablet","genericName":"Digoxin tablet","slug":"digoxin-tablet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ApatinibTablets","genericName":"ApatinibTablets","slug":"apatinibtablets","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HR17031 injection","genericName":"HR17031 injection","slug":"hr17031-injection","phase":"phase_3","mechanism":"HR17031 is an anti-angiogenic agent that inhibits vascular endothelial growth factor (VEGF) signaling to suppress tumor blood vessel formation.","indications":["Solid tumors (specific indications under investigation in phase 3)"],"catalyst":""},{"name":"HRS-8427","genericName":"HRS-8427","slug":"hrs-8427","phase":"phase_3","mechanism":"HRS-8427 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells.","indications":["Cancer (specific indication under Phase 3 evaluation)"],"catalyst":""},{"name":"Noiiglutide Injection","genericName":"Noiiglutide Injection","slug":"noiiglutide-injection","phase":"phase_3","mechanism":"Noiiglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve blood glucose control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Sustained-release Metoprolol Succinate","genericName":"Sustained-release Metoprolol Succinate","slug":"sustained-release-metoprolol-succinate","phase":"phase_3","mechanism":"Metoprolol succinate is a beta-blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline, and slowing the heart rate and reducing its workload.","indications":["Hypertension","Angina pectoris","Heart failure","Atrial fibrillation for rate control"],"catalyst":""},{"name":"Apatinib Mesylate, Gefitinib","genericName":"Apatinib Mesylate, Gefitinib","slug":"apatinib-mesylate-gefitinib","phase":"phase_1","mechanism":"Tyrosine kinase inhibitor of VEGFR-2 and c-KIT","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"Drug: Pegylated rhG-CSF: 100µg/kg","genericName":"Drug: Pegylated rhG-CSF: 100µg/kg","slug":"drug-pegylated-rhg-csf-100-g-kg","phase":"phase_3","mechanism":"Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.","indications":["Chemotherapy-induced neutropenia (CIN)","Severe congenital neutropenia","Idiopathic or cyclic neutropenia"],"catalyst":""},{"name":"FOLFOX4","genericName":"FOLFOX4","slug":"folfox4","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fuzuloparib , Abiraterone acetate and Prednisone","genericName":"Fuzuloparib , Abiraterone acetate and Prednisone","slug":"fuzuloparib-abiraterone-acetate-and-prednisone","phase":"phase_3","mechanism":"This combination uses fuzuloparib (a PARP inhibitor) to block DNA repair, combined with abiraterone acetate and prednisone to suppress androgen production and signaling in castration-resistant prostate cancer.","indications":["Metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair deficiency"],"catalyst":""},{"name":"GEMOX","genericName":"GEMOX","slug":"gemox","phase":"phase_2","mechanism":"Gemcitabine and oxaliplatin combination chemotherapy","indications":["Colorectal cancer"],"catalyst":""},{"name":"HR021618","genericName":"HR021618","slug":"hr021618","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS-1738 Injection","genericName":"HRS-1738 Injection","slug":"hrs-1738-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS-6209 in Combination with Letrozole","genericName":"HRS-6209 in Combination with Letrozole","slug":"hrs-6209-in-combination-with-letrozole","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Herombopag tablets","genericName":"Herombopag tablets","slug":"herombopag-tablets","phase":"phase_3","mechanism":"Herombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on megakaryocyte progenitor cells.","indications":["Thrombocytopenia in patients with chronic liver disease","Immune thrombocytopenia (ITP)"],"catalyst":""},{"name":"Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule","genericName":"Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule","slug":"hetrombopag-olamine-tablet-ciclosporin-soft-capsule","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Imipenem and Cilastatin Sodium","genericName":"Imipenem and Cilastatin Sodium","slug":"imipenem-and-cilastatin-sodium","phase":"marketed","mechanism":"Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while cilastatin prevents imipenem degradation by inhibiting renal dehydropeptidase I.","indications":["Serious bacterial infections including lower respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecological infections, and septicemia","Polymicrobial infections and infections caused by gram-positive and gram-negative aerobic and anaerobic bacteria"],"catalyst":""},{"name":"Irinotecan liposome、5-Fluorouracil、Leucovorin","genericName":"Irinotecan liposome、5-Fluorouracil、Leucovorin","slug":"irinotecan-liposome-5-fluorouracil-leucovorin","phase":"phase_3","mechanism":"This combination regimen uses liposomal irinotecan (a topoisomerase I inhibitor) plus 5-fluorouracil and leucovorin to inhibit DNA replication and repair in cancer cells.","indications":["Metastatic colorectal cancer","Pancreatic cancer (in development)"],"catalyst":""},{"name":"Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan","genericName":"Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan","slug":"ramucirumab-paclitaxel-docetaxel-irinotecan","phase":"phase_3","mechanism":"This is a combination regimen pairing ramucirumab (a VEGF receptor 2 inhibitor) with chemotherapy agents (paclitaxel, docetaxel, or irinotecan) to block tumor angiogenesis while simultaneously attacking cancer cells.","indications":["Advanced gastric cancer or gastroesophageal junction cancer (in combination with chemotherapy)","Non-small cell lung cancer (in combination with chemotherapy)","Colorectal cancer (in combination with chemotherapy)"],"catalyst":""},{"name":"SHR-1209","genericName":"SHR-1209","slug":"shr-1209","phase":"phase_3","mechanism":"SHR-1209 is a humanized monoclonal antibody that blocks the interaction between PD-L1 and its receptors (PD-1 and B7-1) to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"SHR-1314","genericName":"SHR-1314","slug":"shr-1314","phase":"phase_3","mechanism":"SHR-1314 is a small molecule targeting the CD47/SIRPα axis.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"SHR-1316; Carboplatin; Etoposide；Radiotherapy","genericName":"SHR-1316; Carboplatin; Etoposide；Radiotherapy","slug":"shr-1316-carboplatin-etoposide-radiotherapy","phase":"phase_3","mechanism":"Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting cancer cell growth and inducing apoptosis.","indications":["Small cell lung cancer","Non-small cell lung cancer","Ovarian cancer","Testicular cancer","Other cancers"],"catalyst":""},{"name":"SHR2554 analog tablets; Chidamide","genericName":"SHR2554 analog tablets; Chidamide","slug":"shr2554-analog-tablets-chidamide","phase":"phase_3","mechanism":"Chidamide is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and the activation of tumor suppressor genes.","indications":["Relapsed or refractory peripheral T-cell lymphoma","Relapsed or refractory cutaneous T-cell lymphoma"],"catalyst":""},{"name":"SHR3824","genericName":"SHR3824","slug":"shr3824","phase":"phase_3","mechanism":"SHR3824 is a small molecule targeting the molecular target.","indications":["Unknown"],"catalyst":""},{"name":"SHR7280；Ganirelix Acetate Injection simulant","genericName":"SHR7280；Ganirelix Acetate Injection simulant","slug":"shr7280-ganirelix-acetate-injection-simulant","phase":"phase_3","mechanism":"Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion.","indications":["Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology"],"catalyst":""},{"name":"SHR8008 capsule","genericName":"SHR8008 capsule","slug":"shr8008-capsule","phase":"phase_3","mechanism":"SHR8008 capsule is a small molecule drug that targets the molecular target.","indications":["Hypertension"],"catalyst":""},{"name":"SHR8058 eye drops","genericName":"SHR8058 eye drops","slug":"shr8058-eye-drops","phase":"phase_3","mechanism":"SHR8058 is a selective TRPM8 channel antagonist that reduces ocular surface pain and irritation by blocking cold-sensitive ion channels in the eye.","indications":["Dry eye disease (DED) with neuropathic pain component"],"catalyst":""},{"name":"SHR8554 Injection","genericName":"SHR8554 Injection","slug":"shr8554-injection","phase":"phase_3","mechanism":"SHR8554 Injection is a glucagon-like peptide-1 (GLP-1) receptor agonist.","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"Vehicle eye drops.","genericName":"Vehicle eye drops.","slug":"vehicle-eye-drops","phase":"phase_3","mechanism":"Vehicle eye drops serve as a placebo or control treatment in ophthalmic clinical trials.","indications":["Dry eye syndrome","Conjunctivitis"],"catalyst":""},{"name":"Apatinib and Etoposide capsule","genericName":"Apatinib and Etoposide capsule","slug":"apatinib-and-etoposide-capsule","phase":"phase_2","mechanism":"Apatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), while Etoposide is a topoisomerase inhibitor that works by interfering with the enzyme topoisomerase II, thereby inhibiting DNA replication and transcription.","indications":["Metastatic gastric cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"Avastin®, paclitaxel, carboplatin","genericName":"Avastin®, paclitaxel, carboplatin","slug":"avastin-paclitaxel-carboplatin","phase":"phase_3","mechanism":"This combination uses bevacizumab to inhibit tumor angiogenesis while paclitaxel and carboplatin work as chemotherapy agents to kill cancer cells.","indications":["Advanced or metastatic non-small cell lung cancer","Ovarian cancer","Breast cancer"],"catalyst":""},{"name":"BP102, paclitaxel, carboplatin","genericName":"BP102, paclitaxel, carboplatin","slug":"bp102-paclitaxel-carboplatin","phase":"phase_3","mechanism":"BP102 is a nanoparticle albumin-bound paclitaxel combined with carboplatin chemotherapy that disrupts microtubule dynamics and induces DNA crosslinking to kill cancer cells.","indications":["Non-small cell lung cancer (phase 3)","Potentially other solid tumors (under investigation)"],"catalyst":""},{"name":"Camrelizumab Plus Chemotherapy","genericName":"Camrelizumab Plus Chemotherapy","slug":"camrelizumab-plus-chemotherapy","phase":"phase_3","mechanism":"Camrelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer (NSCLC) in combination with chemotherapy","Nasopharyngeal carcinoma in combination with chemotherapy","Esophageal squamous cell carcinoma in combination with chemotherapy"],"catalyst":""},{"name":"Carboplatin for Injection","genericName":"Carboplatin for Injection","slug":"carboplatin-for-injection","phase":"phase_3","mechanism":"Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing apoptosis.","indications":["Ovarian cancer","Lung cancer","Breast cancer","Head and neck cancer","Testicular cancer"],"catalyst":""},{"name":"Carelizumab","genericName":"Carelizumab","slug":"carelizumab","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cipatinib","genericName":"Cipatinib","slug":"cipatinib","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Enzalutamide Soft Capsules","genericName":"Enzalutamide Soft Capsules","slug":"enzalutamide-soft-capsules","phase":"phase_3","mechanism":"Enzalutamide is an androgen receptor inhibitor that blocks the binding and nuclear translocation of androgens, preventing androgen-driven gene transcription in prostate cancer cells.","indications":["Metastatic castration-resistant prostate cancer (mCRPC)","Non-metastatic castration-resistant prostate cancer (nmCRPC)","Metastatic castration-sensitive prostate cancer (mCSPC)"],"catalyst":""},{"name":"FH-006 ; SHR-1316 ; BP102","genericName":"FH-006 ; SHR-1316 ; BP102","slug":"fh-006-shr-1316-bp102","phase":"phase_2","mechanism":"FH-006 is a small molecule drug that targets the molecular target.","indications":["unknown"],"catalyst":""},{"name":"Fluconazole capsule","genericName":"Fluconazole capsule","slug":"fluconazole-capsule","phase":"phase_3","mechanism":"Fluconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","indications":["Candidiasis (oropharyngeal, esophageal, vaginal, and systemic)","Cryptococcal meningitis","Fungal prophylaxis in immunocompromised patients","Other invasive fungal infections"],"catalyst":""},{"name":"Fluconazole、Famitinib","genericName":"Fluconazole、Famitinib","slug":"fluconazole-famitinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fluzoparib Combined With Apatinib","genericName":"Fluzoparib Combined With Apatinib","slug":"fluzoparib-combined-with-apatinib","phase":"phase_2","mechanism":"Fluzoparib is a PARP inhibitor that blocks DNA repair, while apatinib is a VEGFR-2 inhibitor that inhibits angiogenesis, together potentially enhancing antitumor activity.","indications":["Advanced solid tumors"],"catalyst":""},{"name":"Fluzoparib; Apatinib","genericName":"Fluzoparib; Apatinib","slug":"fluzoparib-apatinib","phase":"phase_3","mechanism":"Fluzoparib is a PARP inhibitor that blocks DNA repair, while apatinib is a tyrosine kinase inhibitor targeting VEGFR2, together enhancing anti-tumor effects through synthetic lethality and anti-angiogenesis.","indications":["Ovarian cancer (BRCA-mutated or homologous recombination-deficient)","Gastric cancer","Other solid tumors in phase 3 evaluation"],"catalyst":""},{"name":"HR020602 injection","genericName":"HR020602 injection","slug":"hr020602-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HR070803","genericName":"HR070803","slug":"hr070803","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HR17031 injection ；INS068 injection；SHR20004 injection","genericName":"HR17031 injection ；INS068 injection；SHR20004 injection","slug":"hr17031-injection-ins068-injection-shr20004-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HR19042 Capsules","genericName":"HR19042 Capsules","slug":"hr19042-capsules","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HR19042 capsule","genericName":"HR19042 capsule","slug":"hr19042-capsule","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS-1167","genericName":"HRS-1167","slug":"hrs-1167","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS-4357 injection","genericName":"HRS-4357 injection","slug":"hrs-4357-injection","phase":"phase_3","mechanism":"HRS-4357 is an anti-angiogenic agent that inhibits vascular endothelial growth factor (VEGF) signaling to suppress tumor blood vessel formation.","indications":["Advanced or metastatic solid tumors (specific indications under investigation in Phase 3)"],"catalyst":""},{"name":"HRS-4508 tablet","genericName":"HRS-4508 tablet","slug":"hrs-4508-tablet","phase":"phase_2","mechanism":"HRS-4508 tablet is a small molecule drug that targets the molecular target.","indications":["Unknown"],"catalyst":""},{"name":"HRS-4642 + AG","genericName":"HRS-4642 + AG","slug":"hrs-4642-ag","phase":"phase_3","mechanism":"HRS-4642 is an anti-angiogenic tyrosine kinase inhibitor that blocks multiple receptor tyrosine kinases involved in tumor vascularization and growth.","indications":["Advanced or metastatic solid tumors (specific indication under phase 3 evaluation)"],"catalyst":""},{"name":"HRS-5041 tablets","genericName":"HRS-5041 tablets","slug":"hrs-5041-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS-9190; under Inhalational Anesthesia","genericName":"HRS-9190; under Inhalational Anesthesia","slug":"hrs-9190-under-inhalational-anesthesia","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS-9231","genericName":"HRS-9231","slug":"hrs-9231","phase":"phase_3","mechanism":"HRS-9231 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and angiogenesis.","indications":["Solid tumors (specific indications in phase 3 development)"],"catalyst":""},{"name":"HRS4800 tablets","genericName":"HRS4800 tablets","slug":"hrs4800-tablets","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HS-10296 po","genericName":"HS-10296 po","slug":"hs-10296-po","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hetrombopag Olamine+Standard Therapy","genericName":"Hetrombopag Olamine+Standard Therapy","slug":"hetrombopag-olamine-standard-therapy","phase":"phase_3","mechanism":"Hetrombopag olamine is a thrombopoietin receptor agonist that stimulates platelet production to increase platelet counts.","indications":["Immune thrombocytopenia (ITP)","Thrombocytopenia in patients with chronic hepatitis C"],"catalyst":""},{"name":"INS068 injection","genericName":"INS068 injection","slug":"ins068-injection","phase":"phase_3","mechanism":"INS068 is an anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"Insulin Degludec Injection","genericName":"Insulin Degludec Injection","slug":"insulin-degludec-injection","phase":"phase_3","mechanism":"Insulin degludec is a long-acting basal insulin that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"IvabRadine hemisulfate Sustained-release Tablets","genericName":"IvabRadine hemisulfate Sustained-release Tablets","slug":"ivabradine-hemisulfate-sustained-release-tablets","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Letrozole or Anastrozole Tablets","genericName":"Letrozole or Anastrozole Tablets","slug":"letrozole-or-anastrozole-tablets","phase":"phase_3","mechanism":"Letrozole and Anastrozole are aromatase inhibitors that block the conversion of androgens to estrogen, reducing estrogen levels in postmenopausal women with hormone receptor-positive breast cancer.","indications":["Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic)","Extended adjuvant therapy following tamoxifen in postmenopausal women with early-stage breast cancer"],"catalyst":""},{"name":"Morhpine PCA","genericName":"Morhpine PCA","slug":"morhpine-pca","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nifedipine GTIS","genericName":"Nifedipine GTIS","slug":"nifedipine-gtis","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Palcebo; Carboplatin; Etoposide；Radiotherapy","genericName":"Palcebo; Carboplatin; Etoposide；Radiotherapy","slug":"palcebo-carboplatin-etoposide-radiotherapy","phase":"phase_3","mechanism":"This is a combination regimen using carboplatin and etoposide chemotherapy plus radiotherapy to kill cancer cells through DNA damage and cell cycle disruption, with placebo as a control arm.","indications":["Likely small cell lung cancer or other solid tumors (specific indication not provided)"],"catalyst":""},{"name":"Pegylated rhG-CSF: 100µg/kg","genericName":"Pegylated rhG-CSF: 100µg/kg","slug":"pegylated-rhg-csf-100-g-kg","phase":"phase_3","mechanism":"Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.","indications":["Chemotherapy-induced neutropenia (CIN)","Severe congenital neutropenia","Idiopathic or cyclic neutropenia"],"catalyst":""},{"name":"Placebo+Standard Therapy","genericName":"Placebo+Standard Therapy","slug":"placebo-standard-therapy","phase":"phase_3","mechanism":"This drug is a placebo in combination with standard therapy.","indications":["Various conditions"],"catalyst":""},{"name":"Placebo, Trastuzumab, Docetaxel","genericName":"Placebo, Trastuzumab, Docetaxel","slug":"placebo-trastuzumab-docetaxel","phase":"phase_3","mechanism":"This combination uses trastuzumab to block HER2 signaling in cancer cells while docetaxel disrupts microtubule dynamics to inhibit cell division, with placebo as a control arm.","indications":["HER2-positive breast cancer (metastatic or early-stage)","HER2-positive gastric cancer"],"catalyst":""},{"name":"Placebo、5-Fluorouracil、Leucovorin","genericName":"Placebo、5-Fluorouracil、Leucovorin","slug":"placebo-5-fluorouracil-leucovorin","phase":"phase_3","mechanism":"5-Fluorouracil is a pyrimidine antimetabolite that inhibits thymidylate synthase and gets incorporated into RNA, disrupting nucleotide synthesis and cancer cell division, while leucovorin enhances its efficacy by stabilizing the drug-enzyme complex.","indications":["Colorectal cancer (adjuvant or metastatic)","Gastric cancer","Breast cancer","Pancreatic cancer"],"catalyst":""},{"name":"Placebo、Chemotherapeutic","genericName":"Placebo、Chemotherapeutic","slug":"placebo-chemotherapeutic","phase":"phase_3","mechanism":"This is a placebo control used in chemotherapy clinical trials to establish efficacy of an active chemotherapeutic agent.","indications":["Control arm in chemotherapy clinical trial (specific indication unknown)"],"catalyst":""},{"name":"Pregabalin Release Tablets","genericName":"Pregabalin Release Tablets","slug":"pregabalin-release-tablets","phase":"phase_3","mechanism":"Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.","indications":["Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury pain)","Partial-onset seizures (adjunctive therapy)","Generalized anxiety disorder","Fibromyalgia"],"catalyst":""},{"name":"Pyrotinib in combination with Capecitabine.","genericName":"Pyrotinib in combination with Capecitabine.","slug":"pyrotinib-in-combination-with-capecitabine","phase":"phase_3","mechanism":"Pyrotinib is a tyrosine kinase inhibitor that targets the HER2/neu receptor, and when combined with Capecitabine, it is used to treat HER2-positive breast cancer.","indications":["Metastatic HER2-positive breast cancer"],"catalyst":""},{"name":"Pyrotinib, Trastuzumab, Docetaxel","genericName":"Pyrotinib, Trastuzumab, Docetaxel","slug":"pyrotinib-trastuzumab-docetaxel","phase":"phase_3","mechanism":"Pyrotinib is a tyrosine kinase inhibitor that targets the HER2/neu receptor, while Trastuzumab is a monoclonal antibody targeting the HER2 protein, and Docetaxel is a taxane inhibitor of microtubule assembly.","indications":["Advanced or metastatic breast cancer with HER2 overexpression","Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression"],"catalyst":""},{"name":"RSS0343 Tabella","genericName":"RSS0343 Tabella","slug":"rss0343-tabella","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Remimazolam Tosilate for Injection","genericName":"Remimazolam Tosilate for Injection","slug":"remimazolam-tosilate-for-injection","phase":"marketed","mechanism":"Remimazolam is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors, producing sedation and anxiolysis.","indications":["Procedural sedation and anesthesia induction","Sedation in intensive care units"],"catalyst":""},{"name":"Retagliptin, Henagliflozein, metformin XR","genericName":"Retagliptin, Henagliflozein, metformin XR","slug":"retagliptin-henagliflozein-metformin-xr","phase":"phase_3","mechanism":"Retagliptin, Henagliflozein, and metformin XR work together to lower blood sugar levels by enhancing insulin secretion and suppressing glucagon release, and also by decreasing glucose reabsorption in the kidneys.","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"Rezvilutamide Tablets","genericName":"Rezvilutamide Tablets","slug":"rezvilutamide-tablets","phase":"phase_3","mechanism":"Rezvilutamide is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"],"catalyst":""},{"name":"Rivoceranib (Apatinib)","genericName":"Rivoceranib (Apatinib)","slug":"rivoceranib-apatinib","phase":"phase_3","mechanism":"Rivoceranib (Apatinib) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2).","indications":["Metastatic gastric cancer, Metastatic non-small cell lung cancer"],"catalyst":""},{"name":"SHR-1316、Chemotherapeutic","genericName":"SHR-1316、Chemotherapeutic","slug":"shr-1316-chemotherapeutic","phase":"phase_3","mechanism":"SHR-1316 is a chemotherapeutic agent that inhibits tubulin polymerization to disrupt microtubule dynamics and induce cancer cell death.","indications":["Solid tumors (specific indications under phase 3 evaluation)"],"catalyst":""},{"name":"SHR-A1811","genericName":"SHR-A1811","slug":"shr-a1811","phase":"phase_3","mechanism":"SHR-A1811 is a small molecule targeting the molecular target.","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"SHR-A1811 & Fulvestrant","genericName":"SHR-A1811 & Fulvestrant","slug":"shr-a1811-fulvestrant","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SHR-A1811 Injection ； Pertuzumab Injection","genericName":"SHR-A1811 Injection ； Pertuzumab Injection","slug":"shr-a1811-injection-pertuzumab-injection","phase":"phase_3","mechanism":"Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, inhibiting tumor cell growth signaling.","indications":["HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","HER2-positive early breast cancer (neoadjuvant and adjuvant settings)"],"catalyst":""},{"name":"SHR0302","genericName":"SHR0302","slug":"shr0302","phase":"phase_3","mechanism":"SHR0302 is a small molecule that targets the PI3K/AKT/mTOR pathway.","indications":["Advanced solid tumors","Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"SHR2554 Tablets","genericName":"SHR2554 Tablets","slug":"shr2554-tablets","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SHR2554; Chidamide analog tablets","genericName":"SHR2554; Chidamide analog tablets","slug":"shr2554-chidamide-analog-tablets","phase":"phase_3","mechanism":"Chidamide analog SHR2554 is an inhibitor of histone deacetylases (HDACs), which play a role in regulating gene expression.","indications":["Relapsed or refractory peripheral T-cell lymphoma"],"catalyst":""},{"name":"SHR4640","genericName":"SHR4640","slug":"shr4640","phase":"phase_3","mechanism":"SHR4640 is a small-molecule inhibitor that targets and blocks specific kinase pathways involved in cancer cell proliferation and survival.","indications":[],"catalyst":""},{"name":"SHR6390 Tablets","genericName":"SHR6390 Tablets","slug":"shr6390-tablets","phase":"phase_3","mechanism":"SHR6390 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"SHR7280 simulant； Ganirelix Acetate Injection","genericName":"SHR7280 simulant； Ganirelix Acetate Injection","slug":"shr7280-simulant-ganirelix-acetate-injection","phase":"phase_3","mechanism":"Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion.","indications":["Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART)"],"catalyst":""},{"name":"SHR8028 eye drops","genericName":"SHR8028 eye drops","slug":"shr8028-eye-drops","phase":"phase_3","mechanism":"SHR8028 is a selective rho-associated protein kinase (ROCK) inhibitor administered as eye drops to reduce intraocular pressure in glaucoma.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"SP2086","genericName":"SP2086","slug":"sp2086","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TACE+Camrelizumab+Apatinib mesylate","genericName":"TACE+Camrelizumab+Apatinib mesylate","slug":"tace-camrelizumab-apatinib-mesylate","phase":"phase_3","mechanism":"This combination therapy uses transarterial chemoembolization (TACE) to deliver chemotherapy directly to liver tumors, combined with camrelizumab (a PD-1 inhibitor) to enhance immune response and apatinib mesylate (a tyrosine kinase inhibitor) to block angiogenesis.","indications":["Hepatocellular carcinoma (HCC), unresectable or advanced stage"],"catalyst":""},{"name":"camrelizumab； famitinib malate","genericName":"camrelizumab； famitinib malate","slug":"camrelizumab-famitinib-malate","phase":"phase_3","mechanism":"Camrelizumab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction to enhance T-cell mediated anti-tumor immune response.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Multiple myeloma"],"catalyst":""},{"name":"long-acting Octreotide.","genericName":"long-acting Octreotide.","slug":"long-acting-octreotide","phase":"phase_3","mechanism":"Long-acting octreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors.","indications":["Acromegaly","Neuroendocrine tumors (carcinoid syndrome, VIPomas)","Gastroenteropancreatic neuroendocrine tumors"],"catalyst":""},{"name":"nab-paclitaxel; gemcitabine","genericName":"nab-paclitaxel; gemcitabine","slug":"nab-paclitaxel-gemcitabine","phase":"phase_3","mechanism":"nab-paclitaxel and gemcitabine work together as a chemotherapy combination to disrupt microtubule dynamics and inhibit DNA synthesis, respectively, to kill rapidly dividing cancer cells.","indications":["Pancreatic cancer","Non-small cell lung cancer","Breast cancer"],"catalyst":""},{"name":"placebo+chemotherapy","genericName":"placebo+chemotherapy","slug":"placebo-chemotherapy","phase":"phase_3","mechanism":"This drug works by enhancing the effects of chemotherapy.","indications":["Metastatic breast cancer, Metastatic non-small cell lung cancer"],"catalyst":""},{"name":"saline eye drops.","genericName":"saline eye drops.","slug":"saline-eye-drops","phase":"phase_3","mechanism":"Saline eye drops work by lubricating the eyes to help relieve dryness and irritation.","indications":["Dry eye syndrome","Eye irritation"],"catalyst":""}],"recentEvents":[{"date":"2023-03-15","type":"deal","headline":"Jiangsu Hengrui Medicine Partners with US Biotech Firm to Develop New Cancer Therapies","summary":"The partnership aims to accelerate the development of novel cancer treatments and expand the company's global presence.","drugName":"","sentiment":"positive"},{"date":"2022-06-30","type":"earnings","headline":"Jiangsu Hengrui Medicine Reports 2021 Annual Results","summary":"The company reported a 15% increase in revenue and a 20% increase in net income for the year 2021.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE1LaEowUHRBQ1Z0UEt2S3FiRTRXQnFtZUJINXJKX0p5NFNPUzFvejhKbWdOdy1xbml1bkNQVlljVVR4cmdXZ2xmSU1uV3J1aUNRaVNzUA?oc=5","date":"2026-04-04","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Takeda Pharmaceutical Company Limited (4502.T) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Takeda Pharmaceutical Company Limited (4502.T) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNWHhhTHVqVGNkZmVMT2owTjFzaEx1SllJVDdJclBJWG9ncV82VS1pNjFaY3A0UGRIMDhVYXBXc2hxempYRTFnX2V6RTVTdU9pNHdiQVVaUDZ1WjBReFNDOFE5TXc0ZTBnd0dWQUdBNzR5b292ek9RQ0pkdWxrNURCMEtB?oc=5","date":"2026-01-05","type":"pipeline","source":"Yahoo Finance","summary":"3 of China’s most innovative pharma companies - Yahoo Finance","headline":"3 of China’s most innovative pharma companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPY3JBMGt2U09LOTFfXzc2a1NicTJrVFhXaGgzRmxHVEVkRUN3T1VVcU90UVlBekdnbmJQUkFqRk5ldFo4ZDRvSXVBUWh0cDVsempTMVUyUjFxcjB0eE1KYmtzVllyTjJJTUF5azIxcmV6OUhPU0ZBOUtZaUZqZHRzbDIzSXA1YjF4LUkxZWdOQW1FQmtuQU8yRGY1aWVsaXZMdWtMLWpHbUN2NDZld3ZUVUxQNA?oc=5","date":"2025-09-26","type":"pipeline","source":"Investing.com Australia","summary":"Pharma stocks in Asia fall as Trump announces 100% tariffs By Investing.com - Investing.com Australia","headline":"Pharma stocks in Asia fall as Trump announces 100% tariffs By Investing.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQcWdXeWtNWklQQnhub0pVYjZZZ0Z5TWVmZXpMdDlwNTJybUF3REJHQzdsdmpObFItU3ZzOEtka1FnRnN3RlMwZE1FQzFXd3Q3MExacndIbFhmSEhNSlRfRGdmT2Y4bFZQSy1hcHBSa2RjRWxfM0ZsbS1pa1Y3bzhveHVDMi1GeWdSUlE?oc=5","date":"2025-08-21","type":"earnings","source":"thebambooworks.com","summary":"BRIEF: Surging drug sales drive Hengrui Pharma’s profit growth - thebambooworks.com","headline":"BRIEF: Surging drug sales drive Hengrui Pharma’s profit growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQUGpsODM0QnE0alFCOUc1YVp5dm9pT1ZmN1ZFcGJWeFAwSzRTaGtJODlVaEJJZlVFMGpQVWtpYnZEMFhoQTZkNDJHRDZ5VVhUcHNZLXJxOGNMMjNobTRKUXpXdlBwV01MY1RaVE5abEFBbnB1WjRRbG1WZldmOUxxT19UNWNjdEdUTFBUOEtjUF82bW9nR29MNG5CVm9Ya1pFcEVfUF93ZzhXQTNrZTR4dHVKYlhKRXEycEtRaW1QS2JBWkcySC1BWVBpMi0zR0pXLW9uSFFn?oc=5","date":"2025-07-28","type":"deal","source":"Reuters","summary":"GSK, China's Jiangsu Hengrui strike $500 million drug-development deal - Reuters","headline":"GSK, China's Jiangsu Hengrui strike $500 million drug-development deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNc1dhZldSbUNQQWdIdFRpaHc3RzM1N2xVOE4xNFZXU2psOWN0aHJkYVU0a1h1ZGplaGI3SDVUd0VpMDlSUm45UkhTRTZIY053a0N1SzBvaEphODRFZXVsaGxZWTFQNW1wVjBwcFNmNk9yRzc3bHgwUDdKcUdpeWhGa2prVi1OdnpydGFJc1VXcVl5MDhiNWUyc1ByV0ZRaGRTVmRhN1NSQ2NtYXhVX1JKRA?oc=5","date":"2025-05-23","type":"pipeline","source":"bloomberg.com","summary":"Top Chinese Drugmaker Hengrui Set to Begin Hong Kong Trading - bloomberg.com","headline":"Top Chinese Drugmaker Hengrui Set to Begin Hong Kong Trading","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPcXhHLTNEY1VEQy1WLWg1NzJ4ZFRrVjdScDZMRUp4N1gtV1F4SmxrVXpHVVJZMXNfRGdhTGFDRTZXeXRHT3lnWFlBZ3BzWFFrV3BZSkxERmtXVDFVRDRxQjByclZxNHJ2Rk9lRC16QzV4eFVlZGZWMTR5TXR6UEYwc0Q5M01EQWVER0F0N3l5aFhMV2VaVXE0SGZyYWp4V1dMY0YxbUNhNFNwRzczLUszeVp0QlFtWE5ka3d4Z1BSMlpvMFdoU3owdTZBMW9MM0hvTFhXZ3U1NUJ5QQ?oc=5","date":"2025-05-21","type":"pipeline","source":"Reuters","summary":"China's Jiangsu Hengrui to raise $1.27 billion in Hong Kong listing - Reuters","headline":"China's Jiangsu Hengrui to raise $1.27 billion in Hong Kong listing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE01ZFVYRXB2WW56MWVrY1MtVGVLUnBFV0RWRTM4YWxOV1dvNkZiVGt2bTdDN0JVMXUxUElFNWRnMU9FdjBEUlg1ZXhRTmVlSzZITHpMOVZqekxCTEdUR1AxR3YzVmdRNFQzTDVjQ0RwcWloLXdCcC1yUHRiZXJLMU0?oc=5","date":"2025-03-26","type":"deal","source":"Yahoo Finance","summary":"Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug - Yahoo Finance","headline":"Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE83VHBaY294aGwxeEhGQUNzNUJTQVNpRUxDaUtUMG1fdTl0MDJEVDg2X0xaV2dFRVdWQXlEWlJiUTM5RmtpemIyQ0ljU3JuSXVjS2Y2M21QVVVvV2lRNWFzSHRlOUVkWDQtMW1DYXQ0djc2QVhpNDNXYldEcEZkbmM?oc=5","date":"2025-03-25","type":"pipeline","source":"Yahoo Finance","summary":"Merck Bets $2B on China's Hengrui for Next Big Heart Drug - Yahoo Finance","headline":"Merck Bets $2B on China's Hengrui for Next Big Heart Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPVkJYb3UxdkVWb0c2RUFnM0w2eUNzMFNrLWR2WmZkYldmdXNrRExIdGw2ZW5xQ19iUzNlcmdhV2dQMUdaaEY4TDBCUDdBM3hOQmFkWGdWV0NxcHdhVTZMS0x0bEtONDhHeU5Da0FzSjdOaDBTYUtLN0JnM3Z2R2RZYmNfYkdXc0VXdTlEZm9oY2tJY3BMUFJGemtXSkRIZVVfQkNFTnVuazZTSzJldndSTnZ0U3NucVk2RTRVWTlYaUY4aHhxbXVCcko2ellFblV3SUI2UWNzcHotQ2RBQzZV?oc=5","date":"2025-03-25","type":"deal","source":"Reuters","summary":"Merck buys rights to heart disease drug in latest China deal - Reuters","headline":"Merck buys rights to heart disease drug in latest China deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOUlZvZkFSQW1zRVUtY3hvS0xlSENfWnVRZmRuWHBWZnF4ODlYb2RLdlJ2c05lWEgxbGpkbVE0YXlvUkplZjJBNllJZUxHdjBKRHdPTkN2QVppRWU5cDFJdWRfY1ZfaVFlQUt2U1Z0UnFmeS1ITkpubUo3ZHBZZU1QdFFtQVQzNnlRQ0pPMTB6eENBZFJ5dVphOS1MV0ZiQnVDOFZyeWRRRk5YelJmUFotRFBn?oc=5","date":"2025-03-24","type":"regulatory","source":"Yicai Global","summary":"Hengrui Dips as Chinese Pharma Firm’s New Cancer Drug Fails to Get FDA Nod Again - Yicai Global","headline":"Hengrui Dips as Chinese Pharma Firm’s New Cancer Drug Fails to Get FDA Nod Again","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTFBDdngyWktPV0d1czltc0hfZUxwXzJSWmFKU1RYY2JGMGhweldHTi1aMVRaV0llUThaSWV5TDg2bEpMTE1tU2JaT2lpcHBIMXhjNGp2bjlhNU0yVjQ?oc=5","date":"2018-12-15","type":"pipeline","source":"TradingView","summary":"600276 Stock Price and Chart — SSE:600276 - TradingView","headline":"600276 Stock Price and Chart — SSE:600276","sentiment":"neutral"}],"patents":[{"drugName":"Apatinib","drugSlug":"apatinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":95,"phaseCounts":{"marketed":5,"phase_3":60,"phase_1":11,"phase_2":17,"discontinued":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["BeiGene","Innovent Biologics","Zai Lab"],"therapeuticFocus":["Oncology","Cardiovascular","Autoimmune"],"financials":{"source":"yahoo_finance","revenue":4661599342.713328,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":4661599342.713328},{"period":"2024-12-31","value":4124420668.064258},{"period":"2023-12-31","value":3363220266.19326},{"period":"2022-12-31","value":3135587050.271524}],"grossProfit":4018623406.734462,"grossProfitHistory":[{"period":"2025-12-31","value":4018623406.734462},{"period":"2024-12-31","value":3557269472.775},{"period":"2023-12-31","value":2843663007.6698813},{"period":"2022-12-31","value":2621720039.2992244}],"rdSpend":1025947406.0469187,"rdSpendHistory":[{"period":"2025-12-31","value":1025947406.0469187},{"period":"2024-12-31","value":970201744.7634549},{"period":"2023-12-31","value":730112649.9386569},{"period":"2022-12-31","value":720188778.9497343}],"sgaSpend":1084424299.4113553,"operatingIncome":1266954379.5892916,"operatingIncomeHistory":[{"period":"2025-12-31","value":1266954379.5892916},{"period":"2024-12-31","value":1002657719.5181787},{"period":"2023-12-31","value":681748026.2073606},{"period":"2022-12-31","value":492950856.30853087}],"netIncome":1136468906.7566295,"netIncomeHistory":[{"period":"2025-12-31","value":1136468906.7566295},{"period":"2024-12-31","value":933888567.0866711},{"period":"2023-12-31","value":634100622.6823652},{"period":"2022-12-31","value":575728471.7113861}],"eps":1.18,"epsHistory":[{"period":"2025-12-31","value":1.18},{"period":"2024-12-31","value":1},{"period":"2023-12-31","value":0.68},{"period":"2022-12-31","value":0.61}],"cash":6036091497.306858,"cashHistory":[{"period":"2025-12-31","value":6036091497.306858},{"period":"2024-12-31","value":3657412099.992209},{"period":"2023-12-31","value":3057597667.1330914},{"period":"2022-12-31","value":2227038857.69648}],"totalAssets":10297168663.88272,"totalLiabilities":1189443448.7131124,"totalDebt":10940602.211536858,"equity":9030385927.9325,"operatingCashflow":1655889915.5115404,"operatingCashflowHistory":[{"period":"2025-12-31","value":1655889915.5115404},{"period":"2024-12-31","value":1093978481.1179583},{"period":"2023-12-31","value":1126536887.9699395},{"period":"2022-12-31","value":186476940.9722419}],"capex":-436530990.79552406,"capexHistory":[{"period":"2025-12-31","value":-436530990.79552406},{"period":"2024-12-31","value":-290223811.24036026},{"period":"2023-12-31","value":-218683853.73222935},{"period":"2022-12-31","value":-293610677.22530955}],"freeCashflow":1219358924.7160165,"dividendsPaid":-189275878.2649108,"buybacks":null,"employees":20602,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":414768589.37585366,"ebit":376900924.031631,"ebitda":376900924.031631,"period":"2026-03-31","revenue":1199770925.7757003,"epsBasic":0.34,"netIncome":336364731.81347203,"rdExpense":243271987.0104054,"epsDiluted":0.34,"grossProfit":1038984910.7827548,"operatingIncome":380243390.8958086},{"sga":-228354394.32633606,"ebit":338626429.8563714,"ebitda":338626429.8563714,"period":"2025-12-31","revenue":1244098785.146192,"epsBasic":null,"netIncome":288851360.72769094,"rdExpense":297097600.4787344,"epsDiluted":null,"grossProfit":1072072626.698869,"operatingIncome":343455549.12367016},{"sga":162683040.88836804,"ebit":438618367.11931354,"ebitda":438618367.11931354,"period":"2025-06-30","revenue":1260936893.1418443,"epsBasic":null,"netIncome":379662936.0170925,"rdExpense":249771745.37364578,"epsDiluted":null,"grossProfit":1106731398.3588471,"operatingIncome":413831155.5291992},{"sga":376310571.03450865,"ebit":307516182.5433769,"ebitda":307516182.5433769,"period":"2025-03-31","revenue":1061975721.1981608,"epsBasic":0.3,"netIncome":276201619.6129228,"rdExpense":225966804.6605155,"epsDiluted":0.3,"grossProfit":904474348.00437,"operatingIncome":297443113.64311725},{"sga":-112416755.61125374,"ebit":307319729.0049641,"ebitda":307319729.0049641,"period":"2024-12-31","revenue":1148885332.3056145,"epsBasic":null,"netIncome":253047298.08451343,"rdExpense":299781181.79621094,"epsDiluted":null,"grossProfit":999293614.7891219,"operatingIncome":277217995.9417088}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":54.32,"previousClose":55.86,"fiftyTwoWeekHigh":74.04,"fiftyTwoWeekLow":50.99,"fiftyTwoWeekRange":"50.99 - 74.04","fiftyDayAverage":55.33,"twoHundredDayAverage":61.23,"beta":0.17,"enterpriseValue":47836940642.68706,"forwardPE":31.5,"priceToBook":5.73,"priceToSales":11.07,"enterpriseToRevenue":9.97,"enterpriseToEbitda":34.34,"pegRatio":0,"ebitda":1393178092.3215563,"ebitdaMargin":29,"freeCashflow":929645683.1024845,"operatingCashflow":1689975114.017792,"totalDebt":9944547.20101688,"debtToEquity":0.1,"currentRatio":9.23,"returnOnAssets":8.8,"returnOnEquity":14.5,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0.2,"payoutRatio":0.16,"fiveYearAvgDividendYield":0.38,"exDividendDate":1747958400,"insiderHeldPercent":46.3,"institutionHeldPercent":16.6,"sharesOutstanding":6379002274,"floatShares":3774334655,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":1.22,"epsForward":1.73,"revenuePerShare":4.94,"bookValue":9.48,"officers":[{"age":67,"name":"Mr. Piao Yang  Sun","title":"Executive Chairman of the Board"},{"age":49,"name":"Mr. Hong Bin  Dai","title":"Executive Deputy Chairman of the Board"},{"age":46,"name":"Mr. Kin Chun  Lau","title":"Chief Financial Officer"},{"age":55,"name":"Mr. Jie Ping  Sun","title":"Senior VP & Executive Director"},{"age":63,"name":"Dr. Lian Shan  Zhang Ph.D.","title":"Executive VP & Executive Director"},{"age":64,"name":"Dr. Ningjun  Jiang M.D., Ph.D.","title":"Executive VP, Chief Strategy Officer & Executive Director"},{"age":40,"name":"Ms. Xiao Han  Liu","title":"Board Secretary"},{"age":61,"name":"Mr. Ya Ping  Shen","title":"Deputy General Manager"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"http://www.hrs.com.cn/xwzx01.asp","website":"https://www.hengrui.com","phone":"86 40 0828 3900"}}